DDAVP therapy controls bleeding in Ehlers-Danlos syndrome

Area of Science:

• Hematology
• Genetics
• Pharmacology

Background:

• Ehlers-Danlos syndrome (EDS) is a group of inherited connective tissue disorders characterized by joint hypermobility, skin hyperextensibility, and tissue fragility.
• Patients with certain EDS types (IV, VI, VIII) face elevated bleeding risks, often without identifiable hemostatic defects responsive to conventional therapies.
• Investigating novel therapeutic strategies is crucial for managing bleeding complications in EDS patients.

Observation:

• Two pediatric patients diagnosed with Ehlers-Danlos syndrome (type VIII and type VI) presented with significant hemorrhagic symptoms.
• Both patients were scheduled for surgical procedures, necessitating effective hemostatic management.
• Ivy bleeding times were measured pre- and post-intravenous DDAVP administration to assess its impact on hemostasis.

Findings:

• Intravenous DDAVP administration corrected prolonged Ivy bleeding times in both EDS patients.
• All other laboratory hemostasis tests were within normal limits, indicating a specific response to DDAVP.
• Both patients experienced excellent clinical hemostasis during their surgical procedures.
• One patient successfully utilized intranasal DDAVP for ongoing management of epistaxis and gingival bleeding.

Implications:

• DDAVP demonstrates potential as a therapeutic agent for managing bleeding tendencies in Ehlers-Danlos syndrome.
• This finding suggests DDAVP may be a valuable prophylactic and therapeutic option for EDS patients undergoing surgery or experiencing spontaneous bleeding.
• Further research into DDAVP's efficacy across various EDS subtypes is warranted to establish its role in clinical practice.